A Phase I Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of [GSK461364], a Polo-like Kinase 1 (PLK1) Inhibitor, in Adult Subjects With Advanced Solid Tumor or Non-Hodgkins Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs GSK 461364 (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 07 Oct 2010 Additional location (Northern Ireland) identified as reported by ClinicalTrials.gov.
- 21 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Sep 2009 Planned end date (Mar 2010) added as reported by ClinicalTrials.gov.